ZUVIPLAT (Cisplatin 1mg) INTRAVENOUS INJECTION.

ZUVIPLAT (Cisplatin 1mg) INTRAVENOUS INJECTION.
Generic name: Cisplatin
Brand name: OncoAce
Class: Alkylating agent (Platinum-based chemotherapy).
Pack size: 1 vial.
Form: Injection
Strength: 1mg
Amount: ₦‎15,200

Description: ZuviPlat is a chemotherapy medication used for the treatment of various types of cancer, including testicular, ovarian, bladder, and lung cancers. It contains cisplatin as the active ingredient and is available as a sterile solution for single-dose intravenous infusion. Cisplatin works by inhibiting the growth of cancer cells by forming cross-links in their DNA, leading to apoptosis (cell death). ZuviPlat should only be administered under the supervision of a trained oncologist.

Key features:
• Active Ingredient: Cisplatin
• Strength: 50 mg/50 ml
• Packaging: Vial for intravenous infusion
• Used for the treatment of multiple cancers (testicular, ovarian, bladder, lung)
• Administered via intravenous infusion
• Cytotoxic agent: handle with care.

Side Effects:
• Nausea and vomiting
• Nephrotoxicity (kidney damage)
• Ototoxicity (hearing loss)
• Bone marrow suppression (leading to low blood counts)
• Peripheral neuropathy (numbness or tingling in hands and feet)
• Fatigue
• Electrolyte disturbances (low magnesium, potassium, calcium).

Caution:
• Should only be administered by trained healthcare professionals in a clinical setting.
• Renal (kidney) function should be monitored closely before, during, and after treatment due to the risk of nephrotoxicity.
• Hydration protocols are often required to reduce the risk of kidney damage.
• Cisplatin is highly emetogenic, so anti-nausea medications are typically administered to manage vomiting.
• Caution is needed when used in patients with hearing impairments due to the risk of ototoxicity.
• Handle with care as it is a cytotoxic agent.
• Not recommended for use in pregnant or breastfeeding women due to the risk of harm to the foetus or infant.
• Store in a cool, dry place away from direct sunlight.